GLP-1 Receptor Agonists and SGLT2 Inhibitors Differentially Impact Insulin Resistance Surrogate Markers in Real-World Data

Type 2 Diabetes (T2D) is a global health crisis, with insulin resistance being a core pathophysiological driver beyond mere hyperglycemia. This resistance contributes to a complex atherogenic milieu, encompassing dyslipidemia, endothelial dysfunction, and inflammation, which traditional glycemic indices often fail to capture comprehensively. Current standard-of-care for T2D has evolved to prioritize agents with proven cardiovascular and renal benefits, such as sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). These agents exert effects beyond glucose lowering, influencing body weight, hemodynamics, and lipid metabolism, ultimately impacting insulin sensitivity. The challenge lies in accurately assessing these broader cardiometabolic improvements in routine clinical practice, as gold-standard methods like the hyperinsulinemic–euglycemic clamp are impractical. This highlights the need for accessible surrogate markers that can reflect the multifaceted improvements in insulin resistance and cardiovascular risk. This study aims to compare the effects of these two drug classes on such markers.

This real-world study aimed to compare the effects of SGLT2 inhibitors and GLP-1 receptor agonists on composite surrogate markers of insulin resistance. The researchers utilized two established indices, METS-IR (Metabolic Score for Insulin Resistance) and SPISE (Surrogate index of Insulin Sensitivity), to assess changes in insulin sensitivity. The study design involved analyzing existing clinical data from patients with Type 2 Diabetes receiving either SGLT2i or GLP-1RA therapy. Specific details regarding the patient cohort size, exact drug dosages, treatment duration, and primary endpoints were not provided in the introduction. The study's focus was on a comparative analysis of these two distinct drug classes in a practical, clinical setting.

The provided text is an introduction to the study and does not contain any specific findings, results, or numerical data. Therefore, no quantitative outcomes, p-values, or fold-changes can be reported from this excerpt. The study's objective was to compare the effects of SGLT2 inhibitors and GLP-1 receptor agonists on METS-IR and SPISE as surrogate markers for insulin resistance in patients with Type 2 Diabetes. The introduction sets the stage for the importance of such a comparison given the distinct mechanisms of action and broader cardiometabolic benefits of these drug classes. Without the full text or abstract, the specific differential impacts on these markers remain unstated.